Literature DB >> 28421377

VEP and PERG in patients with multiple sclerosis, with and without a history of optic neuritis.

M Janáky1, Á Jánossy1, G Horváth2, G Benedek2, G Braunitzer3.   

Abstract

PURPOSE: Visual electrophysiology is routinely used to detect the visual complications of multiple sclerosis, but the analysis mostly focuses on visual evoked potential (VEP) and especially the P100 component. Our goal was to analyze the components and waveform alterations of VEPs and pattern electroretinograms (PERGs) in patients with multiple sclerosis (MS) with good vision.
METHODS: The main VEP and PERG components of 85 patients with MS were analyzed in two groups: 38 patients who had optic neuritis in their history (ON group) and 47 patients who had never had optic neuritis (MS group). The results were compared against a control group of 47 healthy subjects.
RESULTS: Both VEP and PERG alterations occurred in a greater number of patients than expected, and these alterations were not necessarily linked to ON in the history or a deterioration of visual acuity.
CONCLUSIONS: Both VEP and PERG can detect dysfunction in the visual system in MS, even if the patient has no subjective symptoms. Even if PERG is not routinely used in neuro-ophthalmology, the results suggest that PERG assessment may provide useful information describing the retinal defect in MS.

Entities:  

Keywords:  Clinical electrophysiology; Multiple sclerosis; Neuromyelitis optica; Ophthalmology; PERG; VEP

Mesh:

Year:  2017        PMID: 28421377     DOI: 10.1007/s10633-017-9589-7

Source DB:  PubMed          Journal:  Doc Ophthalmol        ISSN: 0012-4486            Impact factor:   2.379


  29 in total

1.  Central fiber contribution to W-shaped visual evoked potentials in patients with optic neuritis.

Authors:  J Brecelj; M Strucl; M Hawlina
Journal:  Doc Ophthalmol       Date:  1990-09       Impact factor: 2.379

2.  ISCEV standard for clinical visual evoked potentials: (2016 update).

Authors:  J Vernon Odom; Michael Bach; Mitchell Brigell; Graham E Holder; Daphne L McCulloch; Atsushi Mizota; Alma Patrizia Tormene
Journal:  Doc Ophthalmol       Date:  2016-07-21       Impact factor: 2.379

Review 3.  Pattern electroretinography (PERG) and an integrated approach to visual pathway diagnosis.

Authors:  G E Holder
Journal:  Prog Retin Eye Res       Date:  2001-07       Impact factor: 21.198

Review 4.  Mechanisms of axon-glial injury of the optic nerve.

Authors:  A Compston
Journal:  Eye (Lond)       Date:  2004-11       Impact factor: 3.775

5.  Simultaneous recording of pattern electroretinogram (PERG) and visual evoked potential (VEP) in multiple sclerosis.

Authors:  E Stefano; L M Cupini; P Rizzo; F Pierelli; P A Rizzo
Journal:  Acta Neurol Belg       Date:  1991       Impact factor: 2.396

6.  Optical Coherence Tomography to Assess Neurodegeneration in Multiple Sclerosis.

Authors:  Axel Petzold
Journal:  Methods Mol Biol       Date:  2016

7.  Progressive Loss of Retinal Ganglion Cells and Axons in Nonoptic Neuritis Eyes in Multiple Sclerosis: A Longitudinal Optical Coherence Tomography Study.

Authors:  Elizabeth C Graham; Yuyi You; Con Yiannikas; Raymond Garrick; John Parratt; Michael H Barnett; Alexander Klistorner
Journal:  Invest Ophthalmol Vis Sci       Date:  2016-04-01       Impact factor: 4.799

Review 8.  The history of multiple sclerosis: the changing frame of the disease over the centuries.

Authors:  T Jock Murray
Journal:  J Neurol Sci       Date:  2009-02-01       Impact factor: 3.181

9.  Simultaneous recording of pattern electroretinography and visual evoked potentials in multiple sclerosis. A method to separate demyelination from axonal damage to the optic nerve.

Authors:  G G Celesia; D Kaufman; S B Cone
Journal:  Arch Neurol       Date:  1986-12

10.  Optical coherence tomography and disease subtype in multiple sclerosis.

Authors:  M Pulicken; E Gordon-Lipkin; L J Balcer; E Frohman; G Cutter; P A Calabresi
Journal:  Neurology       Date:  2007-11-27       Impact factor: 9.910

View more
  8 in total

1.  Decoding PERG: A neuro-ophthalmic retinal ganglion cell function review.

Authors:  Pedro Monsalve
Journal:  Curr Ophthalmol Rep       Date:  2019-02-13

Review 2.  Visual Dysfunction in Multiple Sclerosis and its Animal Model, Experimental Autoimmune Encephalomyelitis: a Review.

Authors:  Taekyun Shin; Meejung Ahn; Jeongtae Kim; Kyungsook Jung; Changjong Moon; Moon-Doo Kim
Journal:  Mol Neurobiol       Date:  2021-03-20       Impact factor: 5.590

3.  Comparison of the Structure and Function of the Retina and the Optic Nerve in Patients with a History of Multiple Sclerosis-Related Demyelinating Retrobulbar Optic Neuritis Treated and Not Treated with Systemic Steroid Therapy.

Authors:  Barbara Nowacka; Wojciech Lubiński
Journal:  Clin Ophthalmol       Date:  2021-06-01

4.  Relationship between optical coherence tomography angiography and visual evoked potential in patients with multiple sclerosis.

Authors:  Sedat Ava; Yusuf Tamam; Leyla Hazar; Mine Karahan; Seyfettin Erdem; Mehmet Emin Dursun; Ugur Keklikçi
Journal:  Indian J Ophthalmol       Date:  2022-03       Impact factor: 2.969

Review 5.  The electrophysiological assessment of visual function in Multiple Sclerosis.

Authors:  Joshua L Barton; Justin Y Garber; Alexander Klistorner; Michael H Barnett
Journal:  Clin Neurophysiol Pract       Date:  2019-05-08

6.  Functional Assessment of Outer and Middle Macular Layers in Multiple Sclerosis.

Authors:  Lucia Ziccardi; Lucilla Barbano; Laura Boffa; Maria Albanese; Carolina Gabri Nicoletti; Doriana Landi; Andrzej Grzybowski; Benedetto Falsini; Girolama Alessandra Marfia; Diego Centonze; Vincenzo Parisi
Journal:  J Clin Med       Date:  2020-11-22       Impact factor: 4.241

7.  Colored filters enhancing visual evoked potential (VEP) response in multiple sclerosis.

Authors:  Naveen K Yadav; Valerie L Quan
Journal:  J Optom       Date:  2021-10-20

Review 8.  Clinical electrophysiology of the optic nerve and retinal ganglion cells.

Authors:  Oliver R Marmoy; Suresh Viswanathan
Journal:  Eye (Lond)       Date:  2021-06-11       Impact factor: 3.775

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.